{{medical}}
{{drugbox
| IUPAC_name = 5-chloro-''N''-(4-[''N''-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide
| image = Glibenclamide structural formula V.1.svg
| image2 = Glibenclamide 3D.png
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 10238-21-8
| ATC_prefix = A10
| ATC_suffix = BB01 
| PubChem = 3488
| DrugBank = APRD00233
| IUPHAR_ligand = 2414
| DrugBank2_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank2 = DB01016
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3368
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SX6K58TVWC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00336
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5441
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 472
| C = 23 |H = 28 |Cl = 1 |N = 3 |O = 5 |S = 1
| molecular_weight = 494.004 [[克|g]]/[[摩尔_(单位)|mol]]
| bioavailability = 
| protein_bound = 广泛
| metabolism = [[肝|肝]] [[羟基化|羟基化]] ([[CYP2C9|CYP2C9]]-mediated)
| elimination_half-life = 10 小时
| excretion = 尿液 和 胆汁
| licence_US = Glyburide
| pregnancy_AU = C
| pregnancy_US = B
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服
}}
'''格列苯脲'''（[[International_Nonproprietary_Name|INN]]），又名 '''优降糖'''（[[United_States_Adopted_Name|USAN]]），是一种[[磺酰脲类|磺酰脲类]][[降糖药|降糖药]]。

<!--
It is sold in doses of 1.25 mg, 2.5 mg and 5 mg, under the trade names '''Diabeta''', '''Glynase''' and '''Micronase''' in the [[United_States|United States]] and '''Daonil''', '''Semi-Daonil''' and '''Euglucon''' in the [[United_Kingdom|United Kingdom]]。
-->

市面上也可买到它与[[甲福明二甲双胍|甲福明二甲双胍]]制成的合剂，名为 '''Glucovance'''。

==使用==
用来治疗[[2型糖尿病|2型糖尿病]]。截止到2007年，是[[World_Health_Organization_Model_List_of_Essential_Medicines|世界卫生组织药典]]中两种主要的口服降糖药之一<ref>(March 2007) {{PDFlink|
[http://www.who.int/medicines/publications/EML15.pdf ''WHO Model List of Essential Medicines'']|612 [[Kibibyte|KiB]]<!-- application/pdf, 626969 bytes -->}}, 15<sup>th</sup> edition, [[World_Health_Organization|World Health Organization]]，p. 21. Retrieved on [[2007-11-19|2007-11-19]].</ref>，另一种是[[甲福明二甲双胍|甲福明二甲双胍]]。

在2003年，是美国最流行的降糖药。<ref name="pmid12574174">{{cite journal |author=Riddle MC |title=Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide? |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=2 |pages=528–30 |pmid=12574174 |doi= |url=http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=12574174|date=February 2003}}</ref>

另外，最近的调查表明格列苯脲通过防止脑肿胀改善了动物的发作模型。后续研究发现，与没有使用格列苯脲的患者相比，那些已经服用格列苯脲的[[2型糖尿病|2型糖尿病]]患者的NIH发作比率得到改善。

==作用机制==
本药品通过抑制[[胰岛细胞|胰岛细胞]]的[[ATP敏感钾通道|ATP敏感钾通道]]发挥作用<ref name="pmid17015627">{{cite journal |author=Serrano-Martín X, Payares G, Mendoza-León A |title=Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis |journal=Antimicrob. Agents Chemother. |volume=50 |issue=12 |pages=4214–6 |pmid=17015627 |pmc=1693980 |doi=10.1128/AAC.00617-06 |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=17015627|date=December 2006}}</ref>。 这种抑制使细胞膜去极化、打开[[压敏钙离子通道|压敏钙离子通道]]，导致细胞内的钙离子渗透到[[胰岛细胞|胰岛细胞]]，刺激[[胰岛素|胰岛素]]的释放。

==副作用与禁忌症==
这种药是[[低血糖|低血糖]]的诱因。也有导致胆汁过量造成黄疸的报告。

最近发布的数据表明，去除那些潜在的导致混淆的个例后，格列苯脲与甲福明二甲双胍合用，与其他糖分泌类用药相比导致明显的死亡率升高。这种合用的安全性已被置疑。<ref>{{cite journal | author = Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E | title = Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin | journal = Diabetes Metab Res Rev | volume = 22 | issue = 6 | pages = 477–82 | year = 2006 | pmid = 16634115 | doi = 10.1002/dmrr.642 }}</ref>

==参考==
{{Reflist}}

[[Category:磺酰脲类|Category:磺酰脲类]]
[[Category:World_Health_Organization_essential_medicines|Category:World Health Organization essential medicines]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]